DIStal Versus COnventional RADIAL Access for Coronary Angiography and Intervention

DISCO Radial Trial: DIStal Versus COnventional RADIAL Access for Coronary Angiography and Intervention: a Randomized Multicenter Trial

The objective of this study is to demonstrate the superiority of Distal Radial Access (DTRA) to Conventional Transradial Access (CTRA) regarding forearm radial artery occlusion (RAO).

This trial plans to include 1300 patients in around 12 locations around the world (11 participating sites in Europe and 1 participating site in Japan).

Study Overview

• Status: Completed
• Conditions: Coronary Disease
• Intervention / Treatment: Procedure: Coronary angiography and or Percutaneous coronary Intervention

Detailed Description

DISCO RADIAL is a prospective, global, open label, multi-centre randomized controlled trial with plan to include approximately 1300 patients on who transradial coronary angiography and/or intervention is performed. The patients will be randomized in 1:1 ratio to either Distal Transradial Artery Access (DTRA) or Conventional Transradial Access (CTRA) arm. In both arms 6Fr Glidesheath Slender (GSS) will be used as access sheath.

The sponsor will work in accordance with standard operating procedures (SOP) and the Monitoring Plan in order to ensure adherence to the CIP and applicable regulations at the investigational sites.

The Monitoring Plan is built according to a risk-based monitoring approach and describes the level of source data verification to be performed by the monitors.

Risk-based monitoring approach uses all available means to supervise the trial (central monitoring, remote monitoring and on-site monitoring), focusing in critical data points and issues ensuring that adequate monitoring (central, remote and on-site) at each site is completed to ensure protection of the rights and safety of the subjects and the quality and integrity of the data collected and submitted.

The sponsor shall provide training and the necessary guidelines to assist each investigational site on the data collection in the eCRF. Each site is responsible to report the available data requested by the CIP. In order to ensure data quality and avoid missing information in the eCRF, edit checks are designed during database development. In addition, Sponsor's CRA and Data Management team will be responsible to review the data and raise queries accordingly into the eCRF. An audit trail logging all data entered and edited is available within the EDC system. All source documents are maintained in the hospital files ready for inspection by the Sponsor and regulatory authorities upon request. The Sponsor will inform the investigator of the time period for retaining these records as per applicable regulatory requirements.

The following analysis sets will be considered for the statistical analysis :

As Treated Population This population includes all patients who were treated and undergo the studied procedure. Patients will be assigned to the study treatement groups according to the actual received treatement.

Intention-To-Treat Population This population includes all patients who have been randomized to a treatement. Patients will be assigned to the study treatement groups according to the treatement to which they have been randomized.

Per-Protocol Population This population includes all patients who were treated and undergo the studied procedure, excluding all patients with major violations to the protocol (e.g. wrong inclusion, missing data, mis-randomization, crossover, drop off before discharge). Patients will be assigned to the study treatement groups according to the treatement to which they have been randomized. All the protocol deviations will be reported in statistical report.

Assuming a rate of forearm RAO of 1% in DTRA and 3.5% in CTRA based on on two-sided alpha = 0.050 and power = 80%, 1:1 randomization needs 551 patients for each group to detect statistically significant differences in forearm RAO proportions. Then, given the crossover rate of 10% and the drop out rate of 5% for both group, at least 648 patients needs for each group to maintain proper statistical power. In total 1300 subjects will be randomized.

The primary endpoint analysis will be performed on ITT (Intention-To-Treat) population, by using two-sided superiority test with alpha = 0.05. Due to the short observation period (3 days ±2), a low number of missing data is expected. However, in case it exceeds 15-20%, missing, unused or spurious data will be considered using a tipping point analysis for each population. The comparaison in RAO rates between treatment groups will be tested by Chi-squared tests or Fisher's exact test, as appropriate. Odd-Ratio with IC95% will be calculated. Logistic regression analyses will be used to test the tendency.

• Study Type: Interventional
• Enrollment (Actual): 1309
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Belgium
  • Brussel, Belgium, 1090
    • UZ Brussel
  • Bruxelles
    • Woluwe-Saint-Lambert, Bruxelles, Belgium, 1200
      • Cliniques Universitaires Saint-luc
  • Hainaut
    • Charleroi, Hainaut, Belgium, 6042
      • Hôpital Civil Marie Curie
    • Haine-Saint-Paul, Hainaut, Belgium, 7100
      • CHU Jolimont
• Czechia
  • Plzen, Czechia, 306 05
    • Plzen Medical University
• Germany
  • Minden, Germany, 32429
    • University Hospital Johannes Wesling Klinikum Minden
• Hungary
  • Kecskemet, Hungary, 6000
    • Bacs-kiskun Megyei Korhaz
• Italy
  • Roma, Italy, 00144
    • Sant'Eugenio Hospital
  • Rozzano, Italy, 20089
    • Istituto Clinico Humanitas
• Japan
  • Kanagawa, Japan, 247-8533
    • Shonan Kamakura General Hospital
• Netherlands
  • Zwolle, Netherlands, 8025 AB
    • Isala Hospital
• North Macedonia
  • Skopje, North Macedonia, 1000
    • University Clinic of Cardiology, Skopje
• Switzerland
  • Geneva, Switzerland, 1211
    • HUG Geneva
  • Liestal, Switzerland, CH-4410
    • Kantonsspital Baselland Liestal
• United Kingdom
  • Stoke-on-Trent, United Kingdom, ST4 6QG
    • Royal Stoke University Hospital
  • Sunderland, United Kingdom
    • Sunderland Royal Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patient is at least 18 years of age.
• Patient has provided written informed consent.
• Patient is undergoing diagnostic coronary angiography and/or PCI.
• Patient is willing to comply with all protocol-required evaluations during the hospitalization.
• Patient is suitable for both DTRA and CTRA using 6Fr GSS.

Exclusion Criteria:

• Patient has a medical condition that may cause non-compliance with the protocol and/or confound the data interpretation.
• Patients on chronic hemodialysis.
• Patients presenting with ST-elevated myocardial infarction (STEMI).
• Patients have chronic total occlusion (CTO) lesions in coronary artery.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: SUPPORTIVE_CARE
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
OTHER: Distal Transradial Access	Procedure: Coronary angiography and or Percutaneous coronary Intervention; Radial access punture site
OTHER: Conventional Transradial Access	Procedure: Coronary angiography and or Percutaneous coronary Intervention; Radial access punture site

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Forearm radial artery occlusion (RAO) rate before discharge	Forearm radial artery occlusion (RAO) rate before discharge measured with Doopler Ultrasound	up to 5 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of successful sheath insertion	Rate of successful sheath insertion obtained though eCRF question	up to 2 days
Rate of access site crossover	Rate of access site crossover - if the initial access point fails physician can perform the procedure using other access site of his/her choice This data point is captured on the eCRF	up to 2 days
Total procedural time	Total procedural time defined as the time between initiation of local anesthesia to sheath removal - information captured on the eCRF	up to 2 days
Sheath insertion time	Sheath insertion time recorded in the eCRF and defined as when puncture with the introducer needle first attempted until the time when introducer sheath is successfully inserted	up to 2 days
Puncture site bleeding according to EASY criteria	Puncture site bleeding according to EASY criteria	up to 5 days
Overall bleeding according to BARC criteria	Overall bleeding according to BARC criteria	up to 5 days
Vascular access-site complication	Vascular access-site complication documented on the eCRF. It is composed by the rate of vessel perforation after occlusion requiring intervention, arterial dissection, pseudoaneurysm, and local haematoma	up to 5 days
Rate of radial artery spasm	Rate of radial artery spasm captured in the eCRF. Radial arety spasm is defined as an inability to manipulate the guidewire or catheter in a smooth and pain-free manner and also as an inability to remove the sheath in a similar way at the end of the procedure	up to 2 days
Rate of distal radial artery occlusion (dRAO)	Rate of distal radial artery occlusion (dRAO) by doopler ultrasound and capture in the eCRF	up to 5 days
Patent hemostasis was achieved or not (CTRA) by reverse barbeau test	Patent hemostasis was achieved or not (CTRA) by reverse barbeau test	up to 5 days
Time required to reach hemostasis	Time required to reach hemostasis, captured on the eCRF and defined as the time between sheath removal to complete hemostasis	up to 5 days
Pain associated with the procedure: Visual Assessment Scale (VAS)	Pain associated with the procedure measured by the Visual Assessment Scale (VAS), a numeric rating scale. VAS is a 10 cm line with anchor statements on the left (no pain = 0) and on the right (worst possible pain = 10)	up to 5 days

Collaborators and Investigators

• Sponsor: Terumo Europe N.V.
• Collaborators: Cromsource
• Investigators: Principal Investigator: Adel Aminian, Dr., Hôpital Civil Marie Curie

Publications and helpful links

General Publications

• Kiemeneij F. Left distal transradial access in the anatomical snuffbox for coronary angiography (ldTRA) and interventions (ldTRI). EuroIntervention. 2017 Sep 20;13(7):851-857. doi: 10.4244/EIJ-D-17-00079.
• Corcos T. Distal radial access for coronary angiography and percutaneous coronary intervention: A state-of-the-art review. Catheter Cardiovasc Interv. 2019 Mar 1;93(4):639-644. doi: 10.1002/ccd.28016. Epub 2018 Dec 11.
• Sgueglia GA, Di Giorgio A, Gaspardone A, Babunashvili A. Anatomic Basis and Physiological Rationale of Distal Radial Artery Access for Percutaneous Coronary and Endovascular Procedures. JACC Cardiovasc Interv. 2018 Oct 22;11(20):2113-2119. doi: 10.1016/j.jcin.2018.04.045.
• Aminian A, Saito S, Takahashi A, Bernat I, Jobe RL, Kajiya T, Gilchrist IC, Louvard Y, Kiemeneij F, Van Royen N, Yamazaki S, Matsukage T, Rao SV. Comparison of a new slender 6 Fr sheath with a standard 5 Fr sheath for transradial coronary angiography and intervention: RAP and BEAT (Radial Artery Patency and Bleeding, Efficacy, Adverse evenT), a randomised multicentre trial. EuroIntervention. 2017 Aug 4;13(5):e549-e556. doi: 10.4244/EIJ-D-16-00816.

Study record dates

Study Major Dates

• Study Start (ACTUAL): December 10, 2019
• Primary Completion (ACTUAL): December 28, 2021
• Study Completion (ACTUAL): December 28, 2021

Study Registration Dates

• First Submitted: October 23, 2019
• First Submitted That Met QC Criteria: November 19, 2019
• First Posted (ACTUAL): November 21, 2019

Study Record Updates

• Last Update Posted (ACTUAL): May 24, 2022
• Last Update Submitted That Met QC Criteria: May 23, 2022
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Keywords: Radial Access; Distal Transradial Access; Randomized Multicenter Trial
• Additional Relevant MeSH Terms: Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Coronary Disease
• Other Study ID Numbers: T133E3

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No